GPER deficiency in male mice results in insulin resistance, dyslipidemia, and a proinflammatory state

Endocrinology

Volumn 154, Issue 11, 2013, Pages 4136-4145

  Sharma, Geetanjali ^a   Hu, Chelin ^a   Brigman, Jonathan L ^b   Zhu, Gang ^c   Hathaway, Helen J ^a   Prossnitz, Eric R ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^c BRUKER BIOSPIN CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; CHOLESTEROL; G PROTEIN COUPLED RECEPTOR 30; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GLUCOSE; INSULIN; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOKINE; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE INTOLERANCE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIPID METABOLISM; LIPID STORAGE; LOCOMOTION; MALE; METABOLIC SYNDROME X; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; SUBCUTANEOUS FAT; WEIGHT GAIN;

ADIPONECTIN; ANIMALS; CYTOKINES; DYSLIPIDEMIAS; FEMALE; GENE EXPRESSION REGULATION; GLUCOSE INTOLERANCE; INFLAMMATION; INSULIN RESISTANCE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84886546730     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1357     Document Type: Article

References (58)

1. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88.
2. Simpson ER, Brown KA. Minireview: obesity and breast cancer: a tale of inflammation and dysregulated metabolism. Mol Endocrinol. 2013;27(5): 715-725.
3. Hursting SD, Dunlap SM. Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. Ann NY Acad Sci. 2012;1271: 82-87.
4. Ropero AB, Alonso-Magdalena P, Quesada I, Nadal A. The role of estrogen receptors in the control of energy and glucose homeostasis. Steroids. 2008;73(9-10): 874-879.
5. Brown LM, Clegg DJ. Central effects of estradiol in the regulation of food intake, body weight, and adiposity. J Steroid Biochem Mol Biol. 2010;122(1-3): 65-73.
6. Mauvais-Jarvis F. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. Trends Endocrinol Metab. 2011;22(1): 24-33.
7. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab. 2003;88(6): 2404-2411.
8. Zamboni M, Armellini F, Milani MP, et al. Body fat distribution in pre- and post-menopausal women: metabolic and anthropometric variables and their inter-relationships. Int J Obes Relat Metab Disord. 1992;16(7): 495-504.
9. Toth MJ, Sites CK, Eltabbakh GH, Poehlman ET. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. Diabetes Care. 2000;23(6): 801-806.
10. Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. Increased visceral fat and decreased energy expenditure during the menopausal transition. Int J Obes. 2008;32(6): 949-958.
11. Stubbins RE, Najjar K, Holcomb VB, Hong J, Nunez NP. Oestrogen alters adipocyte biology and protects female mice from adipocyte inflammation and insulin resistance. Diabetes Obes Metab. 2012; 14(1): 58-66.
12. Lobo RA. Metabolic syndrome after menopause and the role of hormones. Maturitas. 2008;60(1): 10-18.
13. Stubbins RE, Holcomb VB, Hong J, Nunez NP. Estrogen modulates abdominal adiposity and protects female mice from obesity and impaired glucose tolerance. Eur J Nutr. 2011;51(7): 861-870.
14. Lemieux C, Phaneuf D, Labrie F, Giguere V, Richard D, Deshaies Y. Estrogen receptor α-mediated adiposity-lowering and hypocholesterolemic actions of the selective estrogen receptor modulator acolbifene. Int J Obes (Lond). 2005;29(10): 1236-1244.
15. Finan B, Yang B, Ottaway N, et al. Targeted estrogen delivery reverses the metabolic syndrome. Nat Med. 2012;18(12): 1847-1856.
16. Newbold RR, Padilla-Banks E, Jefferson WN. Environmental estrogens and obesity. Mol Cell Endocrinol. 2009;304(1-2): 84-89.
17. Alonso-Magdalena P, Laribi O, Ropero AB, et al. Low doses of bisphenolAand diethylstilbestrol impair Ca2+signals in pancreatic α-cells through a nonclassical membrane estrogen receptor within intact islets of Langerhans. Environ Health Perspect. 2005;113(8): 969-977.
18. Cooke PS, Naaz A. Role of estrogens in adipocyte development and function. Exp Biol Med (Maywood). 2004;229(11): 1127-1135.
19. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2): 129-139.
20. Adamczak M, Wiecek A. The adipose tissue as an endocrine organ. Semin Nephrol. 2013;33(1): 2-13.
21. Haluzik M, Parizkova J, Haluzik MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications. Physiol Res. 2004;53(2): 123-129.
22. Turer AT, Khera A, Ayers CR, et al. Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia. 2011; 54(10): 2515-2524.
23. Padmalayam I, Suto M. Role of adiponectin in the metabolic syndrome: current perspectives on its modulation as a treatment strategy. Curr Pharmaceut Design. 2013;19(32): 5755-5763.
24. Taube A, Schlich R, Sell H, Eckardt K, Eckel J. Inflammation and metabolic dysfunction: links to cardiovascular diseases. Am J Physiol Heart Circ Physiol. 2012;302(11):H2148-H2165.
25. Mauvais-Jarvis F, Clegg DJ, Hevener AL. The role of estrogens in control of energy balance and glucose homeostasis. Endocr Rev. 2013;34(3): 309-338.
26. Rogers NH, Perfield JW 2nd, Strissel KJ, Obin MS, Greenberg AS. Reduced energy expenditure and increased inflammation are early events in the development of ovariectomy-induced obesity. Endocrinology. 2009;150(5): 2161-2168.
27. Prossnitz ER, Arterburn JB, Smith HO, Oprea TI, Sklar LA, Hathaway HJ. Estrogen signaling through the transmembrane G proteincoupled receptor GPR30. Annu Rev Physiol. 2008;70: 165-190.
28. Ferrara CM, Lynch NA, Nicklas BJ, Ryan AS, Berman DM. Differences in adipose tissue metabolism between postmenopausal and perimenopausal women. J Clin Endocrinol Metab. 2002;87(9): 4166-4170.
29. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-α knockout mice. Proc Natl Acad Sci USA. 2000;97(23): 12729-12734.
30. Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol. 2011;7: 715-726.
31. Liu S, Le May C, Wong WP, et al. Importance of extranuclear estrogen receptor-α and membrane G protein-coupled estrogen receptor in pancreatic islet survival. Diabetes. 2009;58(10): 2292-2302.
32. Bologa CG, Revankar CM, Young SM, et al. Virtual and biomolecular screening converge on a selective agonist for GPR30. Faculty of 1000 Biology. Nat Chem Biol. 2006;2(4): 207-212.
33. Liu S, Kilic G, Meyers MS, Navarro G, et al. Oestrogens improve human pancreatic islet transplantation in a mouse model of insulin deficient diabetes. Diabetologia. 2013;56(2): 370-381.
34. Haas E, Bhattacharya I, Brailoiu E, et al. Regulatory role of G protein- coupled estrogen receptor for vascular function and obesity. Circ Res. 2009;104(3): 288-291.
35. Martensson UE, Salehi SA, Windahl S, et al. Deletion of the G protein- coupled receptor 30 impairs glucose tolerance, reduces bone growth, increases blood pressure, and eliminates estradiol-stimulated insulin release in female mice. Endocrinology. 2009;150(2): 687-698.
36. Sharma G, Prossnitz ER. Mechanisms of estradiol-induced insulin secretion by the G protein-coupled estrogen receptor GPR30/GPER in pancreatic β-cells. Endocrinology. 2011;152(8): 3030-3039.
37. Wang C, Dehghani B, Li Y, et al. Membrane estrogen receptor regulates experimental autoimmune encephalomyelitis through up-regulation of programmed death 1. J Immunol. 2009;182(5): 3294-3303.
38. Wald D, Teucher B, Dinkel J,. Automatic quantification of subcutaneous and visceral adipose tissue from whole-body magnetic resonance images suitable for large cohort studies. J Magn Reson Imaging. 2012;36(6): 1421-1434.
39. Fahlstrom A, Yu Q, Ulfhake B. Behavioral changes in aging female C57BL/6 mice. Neurobiol Aging. 2011;32(10): 1868-1880.
40. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7): 412-419.
41. Katz A, Nambi SS, Mather K, et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab. 2000;85(7): 2402-2410.
42. Foryst-Ludwig A, Kintscher U. Metabolic impact of estrogen signalling through ERα and ERβ. J Steroid Biochem Mol Biol. 2010; 122(1-3): 74-81.
43. Ribas V, Nguyen MT, Henstridge DC, et al. Impaired oxidative metabolism and inflammation are associated with insulin resistance in ERα-deficient mice. Am J Physiol Endocrinol Metab. 2010; 298(2):E304-E319.
44. Ford J, Hajibeigi A, Long M, Hahner L, Gore C, Hsieh JT, Clegg D, Zerwekh J, Oz OK. GPR30 deficiency causes increased bone mass, mineralization, and growth plate proliferative activity in male mice. J Bone Miner Res. 2011;26(2): 298-307.
45. Langer G, Bader B, Meoli L, et al. A critical review of fundamental controversies in the field of GPR30 research. Steroids. 2010;75(8- 9): 603-610.
46. Poehlman ET. Menopause, energy expenditure, and body composition. Acta Obstet Gynecol Scand. 2002;81(7): 603-611.
47. Ohlsson C, Hellberg N, Parini P, et al. Obesity and disturbed lipoprotein profile in estrogen receptor-α-deficient male mice. Biochem Biophys Res Commun. 2000;278(3): 640-645.
48. Ebbert JO, Jensen MD. Fat depots, free fatty acids, and dyslipidemia. Nutrients. 2013;5(2): 498-508.
49. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis. 2007;17(4): 319-326.
50. Abdul-Ghani MA, DeFronzo RA. Pathophysiology of prediabetes. Curr Diab Rep. 2009;9(3): 193-199.
51. Xing Z, Gauldie J,CoxG, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101(2): 311-320.
52. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998;83(3): 847-850.
53. Vural P, Akgul C, Canbaz M. Effects of hormone replacement therapy on plasma pro-inflammatory and anti-inflammatory cytokines and some bone turnover markers in postmenopausal women. Pharmacol Res. 2006;54(4): 298-302.
54. Arita Y, Kihara S, Ouchi N, et al. Paradoxical decrease of an adipose- specific protein, adiponectin, in obesity. Biochem Biophys Res Commun. 1999;257(1): 79-83.
55. Yamauchi T, Kamon J, Waki H, et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001;7(8): 941-946.
56. Diez JJ, Iglesias P. The role of the novel adipocyte-derived hormone adiponectin in human disease. Eur J Endocrinol. 2003;148(3): 293-300.
57. Revankar CM, Cimino DF, Sklar LA, Arterburn JB, Prossnitz ER. Atransmembrane intracellular estrogen receptor mediates rapid cell signaling. Science. 2005;307(5715): 1625-1630.
58. Dennis MK, Burai R, Ramesh C, et al. In vivo effects of a GPR30 antagonist. Nat Chem Biol. 2009;5(6): 421-427.